
Suzanne George

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3010337/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, The, 2006, 368, 1329-1338.	6.3	2,349
2	Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, The, 2007, 370, 2011-2019.	6.3	973
3	Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 536-563.	2.3	457
4	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity, 2017, 46, 197-204.	6.6	400
5	Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors. Annals of Internal Medicine, 2006, 145, 660.	2.0	356
6	Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. Journal of Clinical Oncology, 2009, 27, 3154-3160.	0.8	295
7	Molecular Subtypes of <i>KIT/PDGFRA</i> Wild-Type Gastrointestinal Stromal Tumors. JAMA Oncology, 2016, 2, 922.	3.4	291
8	Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 758-786.	2.3	239
9	Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2012, 30, 2401-2407.	0.8	232
10	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 923-934.	5.1	224
11	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncology, The, 2020, 21, 935-946.	5.1	186
12	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer, 2017, 123, 3285-3290.	2.0	170
13	Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer, 2014, 120, 3154-3158.	2.0	166
14	Soft Tissue and Uterine Leiomyosarcoma. Journal of Clinical Oncology, 2018, 36, 144-150.	0.8	157
15	Combination mTOR and ICF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors. Clinical Cancer Research, 2011, 17, 871-879.	3.2	150
16	Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. Clinical Cancer Research, 2009, 15, 5902-5909.	3.2	133
17	The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecologic Oncology, 2014, 132, 360-365.	0.6	133
18	BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. American Journal of Surgical Pathology, 2018, 42, 335-341.	2.1	118

#	Article	IF	CITATIONS
19	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. British Journal of Cancer, 2019, 120, 612-620.	2.9	109
20	Leiomyosarcoma. Hematology/Oncology Clinics of North America, 2013, 27, 957-974.	0.9	108
21	Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists. Radiographics, 2016, 36, 767-782.	1.4	105
22	Gastrointestinal Stromal Tumors, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 853-862.	2.3	96
23	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	2.0	96
24	Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer, 2014, 120, 738-743.	2.0	84
25	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer, 2021, 145, 132-142.	1.3	75
26	Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care. Oncologist, 2014, 19, 669-680.	1.9	61
27	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Journal of Clinical Oncology, 2020, 38, 3294-3303.	0.8	61
28	Recent advances in the treatment of gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 2014, 6, 115-127.	1.4	60
29	Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2011, 67, 15-24.	1.1	59
30	Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Clinical Cancer Research, 2020, 26, 5078-5085.	3.2	59
31	Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients. Journal of Gynecologic Oncology, 2014, 25, 306.	1.0	58
32	Uterine Sarcoma, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1321-1331.	2.3	58
33	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. Journal of Clinical Oncology, 2017, 35, 523-528.	0.8	58
34	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Journal of Clinical Oncology, 2021, 39, 3128-3139.	0.8	56
35	Characteristics of mismatch repair deficiency in sarcomas. Modern Pathology, 2019, 32, 977-987.	2.9	49
36	Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. European Journal of Cancer, 2009, 45, 2818-2824.	1.3	44

#	Article	IF	CITATIONS
37	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncology, 2020, 16, 4251-4264.	1.1	43
38	Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Targeted Oncology, 2017, 12, 277-288.	1.7	39
39	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2019, 25, 7287-7293.	3.2	37
40	Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2021, 11, 672500.	1.3	35
41	Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	3.2	34
42	YWHAE -rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecologic Oncology, 2017, 145, 531-535.	0.6	32
43	Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. JCO Precision Oncology, 2019, 2019, 1-11.	1.5	31
44	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer, 2020, 20, 99.	1.1	31
45	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results Journal of Clinical Oncology, 2017, 35, 11005-11005.	0.8	30
46	Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. European Journal of Cancer, 2014, 50, 981-986.	1.3	29
47	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist, 2021, 26, e639-e649.	1.9	29
48	First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies. Clinical Cancer Research, 2013, 19, 909-919.	3.2	26
49	Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. European Journal of Cancer, 2006, 42, 864-870.	1.3	24
50	Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. Oncologist, 2017, 22, 1265-1270.	1.9	24
51	Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Molecular Cancer Research, 2020, 18, 1302-1314.	1.5	24
52	Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. Current Treatment Options in Oncology, 2002, 3, 489-496.	1.3	21
53	Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Current Oncology Reports, 2007, 9, 323-327.	1.8	21
54	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody–Drug Conjugate. Cancer Discovery, 2021, 11, 1508-1523.	7.7	20

#	Article	IF	CITATIONS
55	Risk Factors for Occult Uterine Sarcoma Among Women Undergoing Minimally Invasive Gynecologic Surgery. Journal of Minimally Invasive Gynecology, 2016, 23, 34-39.	0.3	19
56	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the <scp>INVICTUS</scp> Study. Oncologist, 2021, 26, e2053-e2060.	1.9	19
57	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. European Journal of Cancer, 2021, 155, 236-244.	1.3	19
58	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. British Journal of Cancer, 2020, 122, 1158-1165.	2.9	17
59	The role of imatinib plasma level testing in gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2011, 67, 45-50.	1.1	16
60	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. European Journal of Cancer, 2020, 126, 21-32.	1.3	16
61	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2017, 35, 11011-11011.	0.8	16
62	Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors Journal of Clinical Oncology, 2017, 35, 2515-2515.	0.8	16
63	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clinical Cancer Research, 2019, 25, 5135-5142.	3.2	14
64	SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma, 2018, 2018, 1-9.	0.7	13
65	Differentiating leiomyosarcoma from leiomyoma: in support of an MR imaging predictive scoring system. Abdominal Radiology, 2021, 46, 4927-4935.	1.0	11
66	Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus Journal of Clinical Oncology, 2016, 34, 11007-11007.	0.8	11
67	Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clinical Imaging, 2016, 40, 880-884.	0.8	9
68	Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. Clinical Cancer Research, 2022, 28, 1268-1276.	3.2	7
69	Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment. Sarcoma, 2015, 2015, 1-5.	0.7	6
70	Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. JAMA Oncology, 2018, 4, 1169.	3.4	6
71	A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases. Modern Pathology, 2022, 35, 794-807.	2.9	6
72	Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clinical Cancer Research, 2022, 28, 2397-2408.	3.2	6

#	Article	IF	CITATIONS
73	Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation Journal of Clinical Oncology, 2016, 34, 11043-11043.	0.8	4
74	Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors Journal of Clinical Oncology, 2016, 34, TPS11070-TPS11070.	0.8	4
75	Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clinical Cancer Research, 2022, 28, 2579-2586.	3.2	4
76	Superior Vena Cava Syndrome associated with recurrent uterine adenosarcoma. Gynecologic Oncology Reports, 2020, 33, 100613.	0.3	3
77	Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?. Current Treatment Options in Oncology, 2021, 22, 99.	1.3	3
78	Reply to W.F. Pirl et al. Journal of Clinical Oncology, 2009, 27, e51-e51.	0.8	2
79	Linking Genotype to Phenotype: Bench to Bedside. Clinical Cancer Research, 2022, , OF1-OF3.	3.2	1
80	Reply to inâ€bag morcellation for presumed myoma retrieval at laparoscopy. Cancer, 2014, 120, 4005-4005.	2.0	0
81	A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans Blood, 2007, 110, 1791-1791.	0.6	Ο
82	Whole exome analysis of patients (pts) with metastatic GIST (mGIST) demonstrating exceptional survival with imatinib (IM) therapy compared to those with short term benefit Journal of Clinical Oncology, 2017, 35, 11513-11513.	0.8	0
83	PET imaging of Gastrointestinal Stromal Tumors (GIST). , 2022, , .		0
84	Abstract LB565: Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of imatinib resistant GIST. Cancer Research, 2022, 82, LB565-LB565.	0.4	0
85	Abstract CT168: Randomized phase 2 trial of sunitinib or cediranib in alveolar soft part sarcoma. Cancer Research, 2022, 82, CT168-CT168.	0.4	0